Back to top
more

DaVita (DVA)

(Delayed Data from NYSE)

$161.97 USD

161.97
575,208

+1.87 (1.17%)

Updated Oct 18, 2024 04:00 PM ET

After-Market: $161.95 -0.02 (-0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 6% (16 out of 250)

Industry: Medical - Outpatient and Home Healthcare

Better trading starts here.

Zacks News

Merit Medical (MMSI) Inks Deal to Boost Endoscopy Portfolio

Merit Medical's (MMSI) latest asset acquisition is likely to expand its endoscopy portfolio with a minimally-invasive solution for GERD patients, thereby improving patient outcomes.

IceCure Medical (ICCM) New Cryoablation System Gets FDA Nod

IceCure Medical's (ICCM) XSense Cryoablation System receives FDA approval, marking a pivotal step in minimally-invasive tumor treatment across multiple medical fields

Reasons to Retain Revvity (RVTY) Stock in Your Portfolio Now

Revvity's (RVTY) strong product portfolio raises optimism about the stock.

Here's Why You Should Retain Glaukos (GKOS) Stock for Now

Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.

Avantor (AVTR) Launches Solutions for Gene Therapy Harvest

Avantor's (AVTR) solutions are intended to provide gene therapy manufacturers with sustainable and efficient alternatives to traditional methods, thus improving viral particle harvest and quality

Masimo's (MASI) WI Sport Wearable Gets a New Powerful Feature

Masimo (MASI) announces Sleep Halo, a new feature for its Masimo W1 Sport advanced health tracking wearable.

GE Healthcare (GEHC) Enters Partnership to Boost MRI Technology

GE Healthcare's (GEHC) alliance is likely to establish an Innovative MRI Research and Development center to advance MRI innovation and patient care

Reasons to Retain PacBio (PACB) Stock in Your Portfolio Now

PacBio's (PACB) strong product demand and continued focus on R&D raise optimism about the stock.

Tandem Diabetes (TNDM) Posts Positive Data for Tandem Mobi

Tandem Diabetes (TNDM) unveils survey results of the new Tandem Mobi insulin delivery system, underscoring its potential to significantly enhance the quality of life for people with diabetes

PacBio (PACB) and Form Bio to Boost AAV Industry Development

PacBio (PACB) and Form Bio collaborate to form an expert AAV Working Group to introduce essential tools for AAV development and research professionals.

Merit Medical (MMSI) Hits 52-Week High: What's Aiding It?

Investors are optimistic about Merit Medical's (MMSI) strong product portfolio.

Walgreens Boots (WBA) Q3 Earnings Miss, Gross Margin Down

An increasingly challenging pharmacy industry and consumer environment hurt Walgreens Boots' (WBA) bottom line in the third quarter of fiscal 2024.

Reasons to Retain Baxter International (BAX) in Your Portfolio Now

Baxter International's (BAX) robust growth across all geographies, along with transformational initiatives, boosts confidence. However, pandemic-related disruption continues to hurt sales.

Masimo (MASI), Cleveland Clinic Unite to Enhance Patient Care

Masimo (MASI) collaborates with Cleveland Clinic to boost patient care by combining its Hospital Automation platform with the latter's central patient monitoring platforms.

Three Reasons to Retain Merit Medical (MMSI) Stock for Now

Merit Medical's (MMSI) strong product portfolio raises optimism about the stock.

BD's (BDX) New Research Tool to Aid Single-Cell Analysis

BD (BDX) announces the commercial launch of its new single-cell research tool, BD Rhapsody ATAC-Seq Assay, to help researchers understand DNA regulation.

Glaukos (GKOS) Reaches 52-Week High: What's Driving the Stock?

Investors are optimistic about Glaukos' (GKOS) strength in its flagship iStent.

Reasons to Retain Stryker (SYK) Stock in Your Portfolio Now

Stryker (SYK) continues to benefit from strength in the robotic arm-assisted surgery platform Mako and its broad product portfolio.

Here's Why You Should Retain CONMED (CNMD) Stock for Now

CONMED (CNMD) continues to raise optimism among investors, owing to its broad product spectrum.

DaVita HealthCare (DVA) Stock Slides as Market Rises: Facts to Know Before You Trade

In the latest trading session, DaVita HealthCare (DVA) closed at $142.16, marking a -0.53% move from the previous day.

Intuitive Surgical (ISRG) Hits 52-Week High: What's Aiding It?

Investors are optimistic about Intuitive Surgical's (ISRG) strength in robotics.

Ekso Bionics' (EKSO) New Partnership to Aid Its Ekso Devices

Ekso Bionics (EKSO) announces a research partnership with Shepherd Center to create training and research programs for the Ekso devices.

Here's Why You Should Retain HealthEquity (HQY) Stock for Now

HealthEquity's (HQY) sustained strength in HSAs raises optimism about the stock.

Are Medical Stocks Lagging DaVita (DVA) This Year?

Here is how DaVita HealthCare (DVA) and Eledon Pharmaceuticals, Inc. (ELDN) have performed compared to their sector so far this year.

Here's Why You Should Retain Inari Medical (NARI) for Now

Inari Medical (NARI) continues to gain from its expanded product portfolio. However, continued loss at the operating level raises concern.